A series of preclinical and clinical studies on the acquired resistance to sorafenib, a multikinase inhibitor targeting the serine/threonine kinase RAF as well as the VEGF and PDGF receptor tyrosine kinases [27], have demonstrated that downregulation of HTATIP2 by sorafenib in HCC was associated with the activated epithelial-mesenchymal transition (EMT) process and increased invasive and metastatic potentials [28,29,30]. The gene discussed is HTATIP2; the disease is hepatocellular carcinoma.